Organogenesis Holdings Inc. — 2019 Form 10-K Summary
Business context and reporting period
Annual report for the fiscal year ended December 31, 2019, filed March 9, 2020. Organogenesis develops, manufactures and commercializes regenerative-medicine products for Advanced Wound Care and Surgical & Sports Medicine. It reported one operating segment and approximately 835 employees. The filing provides annual, not standalone fourth-quarter, financial results; a clear Q4-only value is not provided in the supplied text.
Key financial metrics
| Metric | 2019 | 2018 |
|---|---|---|
| Net revenue | $261.0 million | $193.4 million |
| Gross profit / gross margin | $185.0 million / 71% | $124.6 million / 64% |
| Operating expenses | $214.5 million | $176.2 million |
| Loss from operations | $29.5 million | $51.6 million |
| Net loss attributable to Organogenesis Holdings | $40.5 million | $64.8 million |
| Adjusted EBITDA (non-GAAP) | $(18.2) million | $(36.2) million |
| Cash used in operating activities | $33.5 million | $60.6 million |
| Cash and working capital at year-end | $60.2 million / $65.7 million | $21.3 million cash |
| Total debt, including capital leases | $100.6 million | $59.3 million |
| Net debt | $40.4 million | $38.0 million |
2019 basic and diluted loss per share was $0.44. Gross margin improved, while the company remained loss-making. The filing does not state a standalone operating or net margin; the reported figures imply an operating loss margin of approximately 11% and a net loss margin of approximately 16%.
Material changes versus 2018
- Revenue rose 35% to $261.0 million. Advanced Wound Care grew 34% to $220.7 million; Surgical & Sports Medicine grew 38% to $40.2 million.
- PuraPly revenue increased to $126.8 million from $69.8 million. Management attributed growth to sales-force expansion, customer gains, broader adoption of amniotic products and restored Medicare pass-through reimbursement effective October 1, 2018.
- Gross margin increased from 64% to 71%, reflecting higher sales and manufacturing efficiencies. SG&A rose 23% to $199.7 million, and R&D rose 38% to $14.8 million, as the company invested in commercial expansion and product development.
- Net loss narrowed by $24.4 million, and operating cash use fell by $27.1 million. Cash increased largely through financing, including $46.8 million net proceeds from a public stock offering and new credit-facility borrowings.
- Debt increased from $59.3 million to $100.6 million, principally reflecting the 2019 credit agreement. Year-end borrowings included a $50.0 million term loan and $33.5 million revolving credit balance.
Outlook, commentary, risks and unusual items
- Management expects operating losses and higher SG&A and R&D expenses to continue in the foreseeable future; SG&A and R&D were expected to increase during 2020. The filing gives no specific revenue or earnings guidance.
- Management expected year-end cash, product-sale cash flows and available credit to fund operations, capital expenditures and debt service for at least 12 months beyond the filing date. This outlook is subject to execution, covenant compliance and access to financing.
- The 2019 credit agreement carries revenue and minimum-liquidity covenants and is secured by substantially all assets, including intellectual property. The company reported covenant compliance at year-end and expected to draw a further $10 million term-loan tranche in March 2020, subject to conditions.
- Medicare pass-through status for PuraPly and PuraPly AM was scheduled to end September 30, 2020. The company warned that reimbursement-policy changes, including a potential single bundled payment, could reduce utilization, pricing or revenue. Private-payer coverage for several products was also limited.
- Affinity production was suspended in the first quarter of 2019 because of supplier problems. The company identified an alternate supplier and expected commercial-scale production no earlier than the second quarter of 2020; replacement of lost revenue was not assured.
- Regulatory uncertainty for human tissue products is material: FDA action could require additional approvals, changes to claims or labeling, or suspension of sales, particularly for NuCel and ReNu. Product adoption also depends on clinical evidence and reimbursement.
- Management identified ineffective disclosure controls and a continuing material weakness in internal control over financial reporting, involving formal accounting controls, reconciliations, journal entries, information systems and segregation of duties. Remediation efforts included added accounting resources and planned ERP implementation.
- Other notable exposures include supplier and donated-tissue availability, competition and pricing pressure, substantial debt and covenant risk, healthcare fraud-and-abuse regulation, and the potential effects of the COVID-19 outbreak noted in the filing.
- In February 2020, the company settled a disputed NuTech Medical deferred-acquisition payment obligation for $4.0 million. This and other subsequent events are after the 2019 year-end.
Most important facts for investors to verify
- Whether PuraPly reimbursement and Medicare payment rules changed after the disclosed pass-through period, and the resulting effect on sales and margins.
- Whether the alternate Affinity supplier achieved commercial-scale output and whether lost Affinity sales were recovered.
- Current cash burn, liquidity, debt service, covenant headroom and the status and terms of any additional credit draw.
- Progress in remediating the material weakness and whether controls operated effectively for a sufficient period.
- 2020 performance of both business lines, including the contribution of PuraPly and the continued growth and profitability of Surgical & Sports Medicine.
- Regulatory developments affecting 361 HCT/P products, including NuCel and ReNu, and the status of planned product launches.